International Clinical Trial: First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07355205) titled 'First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer' on Jan. 19.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Washington University School of Medicine

Condition: Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Recurrent

Intervention: Drug: Ipilimumab Drug: Nivolumab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 31, 2026

Target Sample Si...